Yingkun Hou is a seasoned leader in the life sciences sector, currently serving as the Senior Director of Oncology R&D, Strategy & Competitive Intelligence at AstraZeneca since 2024. They previously held the position of Global Portfolio & Strategy Director for Rare Disease at Novo Nordisk, where they focused on new product planning and strategic initiatives. Yingkun has substantial experience from roles at McKinsey & Company, including Associate Partner, where they specialized in corporate strategy, M&A, and commercial strategy. Yingkun's educational background includes a Master of Science in Chemistry with First Class Honours from Imperial College London and an MBA from INSEAD.
This person is not in the org chart
This person is not in any teams
This person is not in any offices